Tag

Tagged: remote patient monitoring

Sponsored
1 day, 17 hours ago

India and the End of the Fortress Hospital

HealthPad
Directory:
Medical Technology
Tags:
commentary
decentralisation
India
multispecialty hospital
remote patient monitoring

 
  • India’s healthcare growth is real - but the economics of large, bed-heavy hospitals are breaking down
  • Care delivery is decentralising toward asset-light networks, specialty platforms, and local access points
  • MedTech demand is fragmenting, shifting from capital intensity to utilisation-driven, modular models
  • Global incumbents misprice India by applying legacy playbooks to a structurally different care economy
  • If you can succeed in India today, you build the scalable, low-cost operating model that will shape how healthcare is delivered worldwide over the next 10 years

India and the End of the Fortress Hospital

Global MedTech is running out of easy growth. In the US and Europe - together ~73% of the global market - procedure volumes are maturing, capital replacement cycles are stretching, pricing pressure is intensifying, and incremental innovation is delivering smaller marginal gains. Post-pandemic growth has cooled sharply - falling from ~16% in 2021 to low single digits - while shareholder returns have lagged and scrutiny of R&D productivity has intensified. As a result, large diversified MedTechs are increasingly seen as operating in saturated markets with flattening growth profiles.

India has emerged as a prominent counter-narrative.

Now the world’s most populous country (>1.4B people), India is deep into an epidemiological transition toward non-communicable disorders - cardiovascular disease, cancer, diabetes, and chronic respiratory conditions - that directly drive demand for diagnostics, devices, implants, and monitoring technologies. At the same time, a rapidly expanding middle class with rising disposable incomes is increasing utilisation of private healthcare in a system where out-of-pocket spending remains high. On paper, India appears to offer what global MedTech needs most: scale, under penetration, and secular demand growth.

Supply-side signals point in the same direction. Estimates suggest private providers deliver ~70% of outpatient care and ~60% of inpatient care, with an outsized role in tertiary and quaternary services. In major urban centres, they are also the primary buyers - and fastest adopters - of advanced medical technologies. Taken together (and notwithstanding meaningful regional variation), this scale and purchasing power help explain why India features so prominently in boardroom growth narratives and long-range strategic plans across the sector.

But this enthusiasm rests on a flawed assumption: that MedTech growth in India will continue to track the expansion of large, urban, multi-specialty hospitals. That model is reaching its limits. India is no longer short of hospitals; it is short of productive hospitals - and the gap is widening.

A structural shift is underway in India’s hospital estate. Large 500+ bed “fortress hospitals,” once the backbone of private-sector expansion, are increasingly constrained by underutilisation, long breakeven periods, workforce shortages, and declining returns on capital. In contrast, asset light, technology-enabled hub-and-spoke networks - distributed, operationally integrated, and capital-efficient - are scaling faster, attracting investment, and capturing demand closer to where patients live. Growth is increasingly flowing toward models that minimise fixed assets, leverage partnerships, and use technology to expand reach and utilisation.

For US MedTech leaders, this is not a peripheral emerging-market nuance. It is a strategic inflection point. Whether India becomes a durable engine of value creation - or a large but structurally margin-dilutive market - will depend less on how big the opportunity is, and more on how the healthcare system scales from here.
 
In this Commentary

This Commentary examines how India’s healthcare system is structurally reshaping - and why legacy hospital-centric assumptions are becoming less relevant. It traces the shift toward decentralised, asset-light care models and the implications for MedTech demand, economics, and strategy. The core thesis is clear: India is forging new care architectures, and Western companies that adapt early will build advantages that extend beyond India's borders.
 
The Bed Count Fallacy

Over the past two decades, India has added substantial hospital capacity, driven primarily by private-sector expansion and the proliferation of large, multi-specialty tertiary hospitals. In Western board decks and investor presentations, this growth is often interpreted linearly: more beds imply more procedures, higher utilisation, and therefore rising MedTech demand. For executives accustomed to hospital systems in the US or Western Europe, this logic feels intuitive and transferable.

The reality in India, however, is more complex. Private providers account for ~60–65% of the country’s hospital beds, but this concentration of capacity masks variation in utilisation, profitability, and long-term sustainability across regions and service lines. Bed count has ceased to function as a reliable proxy for economic strength.
Healthcare doesn’t need safer strategies - it needs sharper ones. In the latest episode of HealthPadTalks, Diversification Is a Trap, we dismantle the “well-diversified” leadership myth and argue that hedging is a slowdown in an AI, platform-driven world. As value shifts from factories to data, learning speed, and software intelligence, competitive advantage comes from choosing the right complexity - and committing deeply enough for compounding to begin. 
Despite the addition of tens of thousands of beds, a significant share of this capacity remains under-utilised and, more critically, under-productive in economic terms. This is not a cyclical issue driven by temporary demand softness. It is structural. Many large private hospitals - particularly facilities with >500 beds - struggle to achieve sustained occupancy levels that support viable economics. Utilisation frequently settles in the 55-65% range, below the thresholds required to absorb fixed costs, amortise capital expenditure, and generate returns commensurate with risk.

This gap is not marginal. It reflects a misalignment between how India’s hospital infrastructure was built and how care is increasingly accessed and consumed. The assumed economies of scale no longer apply.

On paper, large tertiary hospitals appear advantaged by size and scope. In practice, their financial arithmetic is unforgiving. Capital expenditure per bed in large Indian private hospitals - factoring in land, construction, operating rooms, ICUs, advanced diagnostics, and specialty infrastructure - typically ranges from ~US$85,000 to US$145,000. A 500+ bed facility therefore locks in hundreds of millions of dollars in upfront capital, with breakeven timelines commonly extending eight to twelve years even under optimistic assumptions on utilisation and pricing.

At sub-optimal occupancy, many of these assets struggle to earn their cost of capital. Real-estate appreciation and patient volume growth, which once masked operational inefficiencies, are no longer reliable cushions. What appears as scale on paper increasingly translates into financial fragility in practice.
 
When Bed Count Stops Paying the Bills

Many of India’s large hospitals were designed for an earlier phase of the healthcare market. That phase assumed patients would travel across cities for specialist consultations and routine care, that high-skill clinicians could be recruited, centralised, and retained within flagship facilities, and that long capital horizons - supported by rising real-estate values - would compensate for operational inefficiencies.

Those assumptions no longer hold.
You might also like:
 
Today, large tertiary hospitals operate within a different set of constraints. Fixed-cost structures remain high, while shortages of specialised clinicians and allied health staff have become persistent rather than episodic. At the same time, patient behaviour has shifted toward localisation. Care is increasingly accessed closer to home, with tertiary centres reserved for episodes of clinical complexity rather than routine engagement.
This shift is most visible in outpatient departments (OPDs), which function as the primary feeders for inpatient admissions. OPD activity is fragmenting geographically, dispersing across smaller hospitals, specialty clinics, diagnostic centres, and asset-light care models. Routine consultations, diagnostics, and follow-ups are no longer anchored to distant, monolithic hospitals.

As OPD footfalls decentralise, the inpatient pipeline weakens. Even hospitals with strong clinical reputations and advanced tertiary capabilities face structurally lower utilisation. The challenge is not competitive positioning or brand strength alone, but a care-delivery model increasingly misaligned with how demand is generated and sustained.
 
The Rise of Asset-Light Care Models

As patient demand decentralises and utilisation at large tertiary hospitals remains structurally constrained, care delivery is increasingly migrating toward asset-light models. These models are not peripheral experiments. They are emerging as the primary growth engines across multiple segments of India’s healthcare system.

Asset-light providers are designed around focused service lines rather than comprehensive infrastructure. They emphasise outpatient care, day procedures, diagnostics, and specialty-led pathways that require limited inpatient capacity or none. Capital intensity is lower, breakeven timelines are shorter, and returns are less dependent on sustaining high system-wide occupancy.

This structural advantage is reinforced by clinical labour dynamics. Specialised clinicians are increasingly unwilling to be fully anchored to a single, large institution. Asset-light platforms allow physicians to operate across multiple sites, concentrate on high-value procedures, and reduce administrative and non-clinical burdens. For hospitals built around large, centralised staffing models, this represents a competitive asymmetry.

From the patient perspective, these models align more closely with evolving expectations. Proximity, convenience, and speed increasingly outweigh the perceived value of scale. Routine consultations, diagnostics, and follow-ups are delivered locally, while complex interventions are escalated. The result is a care pathway that is unbundled by design rather than constrained by infrastructure.

Importantly, asset-light growth is not limited to greenfield entrants. Established hospital groups like Apollo, Fortis, Max and Narayana, are reconfiguring their networks through spoke facilities, specialty centres, partnerships, and management contracts. In doing so, they are acknowledging the limits of fortress-style hospitals as the organising unit of care delivery.

The implication is structural, not incremental. As demand shifts toward decentralised, lower-capital formats, economic power within the system follows. Growth accrues to models that convert patient volume into returns without requiring large, under-utilised balance sheets. In this environment, scale is no longer defined by bed count, but by the efficiency with which care is distributed, accessed, and monetised.
 
The Decentralisation Dividend

The decentralisation of care delivery and the rise of asset-light models are reshaping MedTech demand in India in ways that differ from historical assumptions. Demand is not disappearing, but it is fragmenting - shifting away from large, episodic capital purchases toward more distributed, utilisation-driven consumption.

In fortress-style hospitals, MedTech demand was anchored to large capital equipment, installed base expansion, and periodic upgrades justified by scale. By contrast, in asset-light environments, purchasing behaviour is more selective. Capital budgets are tighter, return thresholds are higher, and equipment must demonstrate rapid payback tied to throughput rather than institutional prestige.

This favours technologies that are modular, scalable, and deployable across multiple sites. Compact imaging, ambulatory surgical equipment, point-of-care diagnostics, and digitally enabled monitoring solutions align more closely with decentralised care pathways. Products designed for high-acuity, high-capex tertiary settings face a narrowing addressable market unless they can be adapted to lower-intensity formats.

Consumables and procedure-linked technologies gain relative importance in this shift. As providers prioritise asset efficiency over asset ownership, variable-cost models become more attractive than fixed-capital investments. Recurring revenue streams tied to procedure volume, rather than bed count, better match provider economics in a fragmented delivery landscape.
The sales motion is also changing. Decision-making authority is increasingly distributed across specialty heads, regional operators, and platform-level procurement teams rather than central hospital administrations. Sales cycles are shorter and more heterogeneous, requiring MedTech companies to manage a broader set of customer archetypes with differing economic constraints.

For MedTech portfolios built around assumptions of centralised scale, these shifts create friction. Growth strategies anchored to flagship hospital wins, national tenders, or top-tier academic centres are no longer sufficient. Sustainable growth increasingly depends on breadth of deployment, ease of integration, and the ability to support multi-site, specialty-driven operating models.
You might also like to listen to:

MedTech’s Global Reset: 2025
The implication is not a contraction of opportunity, but a redefinition of it. MedTech demand is moving closer to the point of care, more tightly coupled to utilisation, and less forgiving of capital inefficiency. Portfolios that align with this reality will compound. Those that remain optimised for an earlier hospital paradigm will struggle to convert market presence into durable returns.
 
The India Discount Few Model Correctly

Incumbents entering or expanding in India often misprice the market by extrapolating familiar models onto a different care economy. The error is not one of optimism, but of misplaced assumptions about how value is created, captured, and sustained.

The first mispricing lies in equating market size with spending power. India’s patient volumes are vast but purchasing decisions are constrained by unit economics at the provider level. High procedure counts do not automatically translate into willingness or ability to absorb capital-intensive technologies. Incumbents that size the opportunity through population metrics or disease prevalence alone overestimate near-term monetisation.

A second mispricing arises from overvaluing institutional scale. Large hospital brands and national chains appear to offer efficient access to the market, but they represent only a portion of where care is delivered and decisions are made. As care decentralises, demand fragments across specialty centres, ambulatory facilities, diagnostics networks, and physician-led platforms. Incumbents that concentrate resources on flagship accounts miss the broader, more durable sources of growth.

Pricing architecture is frequently misaligned. Products designed for high-margin, reimbursement-led markets struggle in environments where payback periods are scrutinised at the procedure level. Indian providers price risk aggressively and expect equipment to earn its cost quickly and transparently. Solutions that require behavioural change, cross-subsidisation, or long utilisation ramps face structural resistance, regardless of clinical merit.

Operating complexity is also underpriced. India is often treated as a single market with minor regional variation. Differences in case mix, payer composition, clinician availability, and procurement processes are substantial across states and even cities. Incumbents that rely on uniform national strategies find that execution friction, rather than competition, becomes the limiting factor.

Finally, many incumbents misprice time. India rewards patience, but only when paired with structural adaptation. Early presence without localisation of portfolio, pricing, service, and commercial models rarely compounds into leadership. Conversely, companies that align offerings with provider economics, support decentralised deployment, and invest in long-term clinician and operator relationships often achieve scale that is difficult to dislodge.

The Indian care economy does not penalise incumbents for being global. It penalises them for being rigid. The opportunity is vast, but it accrues to those willing to reprice their assumptions - about scale, capital, demand, and speed - and redesign their approach accordingly.
 
A Playbook for Winning in India

Winning in India over the next decade will not be determined by early entry, brand recognition, or the size of legacy footprints. It will be determined by the ability to align strategy with the structural realities of how care is delivered, financed, and consumed.

The first requirement is a redefinition of scale. In India, scale is no longer synonymous with bed count, flagship hospitals, or centralised procurement. It is defined by breadth of deployment across decentralised care settings and by the efficiency with which products convert utilisation into returns. Companies that design for distributed volume rather than concentrated capacity will compound faster and more predictably.

Second, portfolios must be built around provider economics, not clinical ambition. Technologies that enable faster payback, support modular expansion, and flex across asset-light formats will outperform those optimised for capital-heavy environments. Recurring, procedure-linked revenue models are structurally advantaged in a system where fixed costs are under pressure.

Third, go-to-market models must match the fragmentation of demand. This requires moving beyond reliance on a narrow set of national accounts toward engaging specialty heads, regional operators, and platform-level decision-makers. Sales excellence in India is less about uniform coverage and more about segmentation discipline, local execution, and economic fluency at the point of decision.

Fourth, localisation is no longer optional. Products, pricing, service models, and training must be adapted to regional variation in case mix, staffing, and payer dynamics. Standardised global playbooks create friction in a market that rewards contextual precision. The most successful incumbents will be those that embed India-specific design and operating authority within their organisations.

Finally, time must be treated as a strategic asset. India rewards sustained commitment, but only when paired with continuous adaptation. Patience without learning stalls. Speed without alignment misfires. Durable leadership emerges from iterative presence, long-term clinician relationships, and an operating model designed to evolve alongside the care economy itself.

India’s healthcare market is neither a scaled-down version of developed systems nor a transient growth opportunity. It is a structurally distinct ecosystem that is shaping new models of care delivery. Companies that learn to win here will not only unlock India’s potential but also build capabilities that travel across the next generation of global healthcare markets.
 
Takeaways
 
  • India is not a derivative market. It is a structurally distinct care ecosystem reshaping how healthcare is delivered, financed, and scaled. Winning in India builds capabilities that matter globally.
  • US MedTech leaders face a strategic inflection point. One path extends familiar playbooks - incremental revenue from legacy hospital assets whose economics are weakening and whose system-level influence is declining. This path offers comfort and predictability, but limited durability.
  • The alternative path runs through India’s re-architected care system. Advantage is shifting toward network builders, platform operators, and population-scale orchestrators redefining care delivery. Partnering here is harder - but strategically decisive.
  • The shift is structural, not cyclical. Networks will continue to outperform buildings. Platforms will outperform standalone products. Intelligence, integration, and distributed scale will outperform volume-based selling.
  • Early alignment compounds. Companies that adapt now will not only win in India - but they will also develop operating models, economics, and capabilities that travel across the next generation of global healthcare markets.
view in full page
7 months ago

HealthPadTalks: When The Scalpel Sleeps

HealthPad
Directory:
Medical Technology
Tags:
AI
commentary
HealthPadTalks
MedTech
patient engagement
podcast
remote patient monitoring
value-based healthcare

MedTech’s old playbook is dead. In this episode, we uncover how AI, digital health, and remote care are reshaping the healthcare landscape — moving from more surgeries to fewer, from intervention to prevention. The future of medicine isn’t about placing more devices in the OR, it’s about keeping patients healthy enough to stay out of it.

view in full page
11 months, 3 weeks ago

Disrupt or be Disrupted

HealthPad
Directory:
Medical Technology
Tags:
AI
commentary
Disciplined M&A
MedTech
personalised medicine
remote patient monitoring
Startup
virtual care
virtual healthcare
  • AI-driven diagnostics, virtual care, and advanced analytics are transforming healthcare, enhancing outcomes and efficiency
  • To remain competitive, healthcare organisations must actively invest in digital transformation, forging strategic partnerships and embracing innovation
  • Leveraging AI and targeted M&A is essential for expanding capabilities, accelerating growth, and securing market leadership
  • This Commentary offers a strategic roadmap for capitalising on digital health, emphasising collaboration, talent development, and agility
 
Disrupt or be Disrupted

"We need to ensure that we have an environment here that’s conducive to creativity, to boldness, to new ideas, to recognising the dynamic world in which we live - one that is changing faster than it has ever changed before." These words, spoken by Marco Rubio on January 21, 2025, just hours after being sworn in as America’s Secretary of State, were meant to inspire diplomats navigating an unpredictable global landscape. Yet, they also serve as a clarion call for an industry at a crossroads - healthcare.

Healthcare is not immune to the forces of disruption. On the contrary, it is being upended by digital innovation at a pace that traditional institutions struggle to match. AI-powered diagnostics, virtual care platforms, precision medicine, and wearable biosensors are redefining how care is delivered, driving better patient outcomes, lowering costs, and expanding access. And yet, many of the boldest advancements - the very ones with the potential to reshape the industry - come not from established institutions but from start-ups, outsiders, and unorthodox thinkers.

These disrupters, often found at the periphery, are sometimes unpolished and undiplomatic. Lacking the silver tongue of seasoned executives and the political correctness of corporate boardrooms, they challenge long-held assumptions and force uncomfortable conversations. Their ideas can be raw, their methods unconventional, but their impact is valuable. However, since they are different to traditional norms - failing to align with established structures - they are often dismissed, marginalised, or resisted by incumbents who, whether knowingly or not, seek to preserve the status quo.

Yet, history has shown that industries that ignore or suppress disruption do so at their peril. The digital health revolution is not a passing trend but an irreversible shift, evidenced by ~$10bn in venture funding that flowed into health-tech start-ups in 2024 alone. The question for healthcare leaders is clear: Will they embrace the agents of change and harness their disruptive power or will they resist, only to find themselves disrupted?
 
In this Commentary

This Commentary explores the shift underway in healthcare as digital innovation redefines care delivery, operational models, and competitive dynamics. It explores the rise of AI, virtual care, and precision medicine, showcasing how disrupters - often start-ups and unconventional players - are reshaping traditional institutions. With billions in venture funding fuelling digital health, the Commentary urges healthcare leaders to adapt to disruption or risk being left behind in an increasingly tech-driven landscape.
 
Leveraging Disrupters

Revenue Diversification and Growth Opportunities
Healthcare organisations, whether providers, insurers, or technology developers, are operating in an era of significant change, driven by digital health innovations that are redefining traditional business models. Historically, the sector has been dominated by capital-intensive infrastructure and human-intensive processes, such as surgical interventions, diagnostic imaging, and administrative workflows. While these remain fundamental, the advent of software-driven solutions and data-centric care models presents new revenue opportunities that transcend conventional market limitations.

Start-ups have emerged as primary incubators for disruptive technologies, pioneering advancements in AI-enabled diagnostics, virtual care ecosystems, and remote patient monitoring. These innovations not only enhance clinical efficiency but also introduce scalable, subscription-based revenue models that provide long-term financial sustainability. Established enterprises that fail to integrate such advancements risk stagnation, while those that actively embrace disrupters are better positioned to leverage digital tools that can unlock new revenue streams, drive operational efficiencies, and enhance patient outcomes.

Investment trends affirm this paradigm shift. In 2024, funding for digital health spanned diverse clinical domains, from cardiovascular care to mental health, with start-ups securing billions. This underscores the investment community’s recognition of digital solutions and services as catalysts for growth. Healthcare incumbents must actively scout, partner with, or acquire disruptive players to mitigate reliance on legacy offerings and tap into high-growth market segments that promise sustained profitability.

Enhancing Valuations Through Innovation
In today’s investment landscape, entities within the sector are assessed not only on their present performance but also on their capacity for innovation and agility. Venture capital firms such as Andreesen Horowitz and General Catalyst are making decisive investments in AI platforms, recognising their ability to transform clinical workflows, improve patient engagement, and optimise financial outcomes. This trend signals a broader industry shift - companies that harness technologies command higher valuations and attract stronger investor interest.

For established enterprises, the case for digital transformation is not only strategic but financial. Mergers and acquisitions in this space have surged, with deals targeting AI-driven decision support, analytics-powered risk stratification, and virtual care infrastructure. These investments create synergies that enhance efficiency, strengthen market positioning, and elevate financial performance. Providers, insurers, and life sciences companies must rethink their innovation strategies - not just as an enhancement to existing operations but as a core driver of valuation and competitive differentiation.

Competitive Advantage in a Changing Landscape
Healthcare is witnessing an unprecedented shift, where agility and technological adoption define market leadership. Large incumbents often struggle with structural inertia, as long-tenured executives grapple with managing disrupters while prioritising the stewardship of legacy offerings in increasingly saturated markets. However, the rapid proliferation of digital health start-ups is reshaping competitive dynamics, and established enterprises that do not proactively engage with disrupters risk losing their competitive edge.

Start-ups are leading the charge in AI, telehealth, and remote patient monitoring, capturing ~37% of all digital health funding in 2024. This signals a market appetite for next-generation healthcare solutions. Forward-thinking enterprises must not only acknowledge but actively pursue collaboration, investment, or acquisition strategies that integrate these innovations into their existing frameworks.

Strategic alliances with disrupters accelerate the adoption of cutting-edge technologies, and reinforce an organisation’s reputation as a leader in innovation, attracting top talent, fostering investor confidence, and securing long-term competitive advantage.

Sustainability Through Innovation
Sustainability extends beyond financial and environmental considerations; it encompasses the capacity to continuously evolve while maintaining high standards of care. Digitalisation is redefining sustainability by addressing systemic challenges such as cost efficiency, equitable access, and resource optimisation.

AI-driven analytics enhance diagnostic accuracy and streamline workflows, allowing clinicians to focus on patient-centred care. Virtual care platforms eliminate geographical barriers, expanding access to underserved populations while reducing operational overhead. Predictive modelling empowers insurers and healthcare systems to implement proactive interventions, improving population health management and reducing unnecessary hospitalisations.

Additionally, the shift towards value-based care necessitates advanced technological capabilities to ensure compliance, optimise reimbursement structures, and improve care quality. Digital solutions facilitate real-time data capture, regulatory adherence, and personalised treatment pathways, positioning organisations for long-term resilience in a rapidly evolving regulatory environment.
A new episode of HealthPadTalks is now available

Click here to listen to Can We Survive the Storm? Battling Antimicrobial Resistance and Climate Change for Global Health
Key Trends

Early Investment Surge
In 2024, ~63% of funding rounds targeted early-stage start-ups, marking a significant increase from 2023. This surge highlights a pipeline of innovation driven by emerging companies. Stakeholders - ranging from providers and payers to technology vendors - should leverage this momentum by engaging with start-ups through strategic investments, partnerships, or incubation programmes. Early-stage investments offer a dual advantage: access to pioneering technologies and the opportunity to shape their development in alignment with industry needs.

Notable deals, such as Regard’s $61m Series B funding for clinical decision software, illustrate how established players can incorporate emerging solutions to enhance operational efficiency and patient outcomes. By collaborating with innovative start-ups, organisations can expand into high-growth areas such as decision support systems, patient engagement tools, and population health management.

AI’s Dominance in Healthcare Innovation
The investment trend we have highlighted shows the increasing acknowledgment of the transformative potential of AI. Advancements in this space span a wide range of applications, from optimising clinical workflows to enhancing patient-centric solutions. Trailblazers such as Hippocratic AI and Infinitus exemplify this momentum, offering technologies that simplify administrative tasks, improve diagnostic precision, and deliver personalised care with unprecedented efficiency.

Integrating AI into established portfolios is important. Whether through partnerships, acquisitions, or in-house development, AI can improve operational efficiencies, optimise resource allocation, and deliver more personalised and predictive care. Staying ahead in the AI race enables organisations to remain competitive and meet the evolving expectations of patients and providers.

Strategic M&A as a Growth Lever
M&A in digital health is accelerating as organisations seek solutions that address a broad spectrum of healthcare needs. Analysts predict that 2025 will bring an increased wave of M&A activity, offering opportunities for players to expand their capabilities through targeted acquisitions.

Examples like DarioHealth’s acquisition of Twill and Fabric Health’s series of strategic purchases demonstrate how M&A can create end-to-end virtual care platforms and broaden market reach. By adopting a similar approach, stakeholders can accelerate entry into high-demand segments such as telehealth, chronic care management, and AI-powered diagnostics, while creating synergies that enhance scalability and innovation.

The Rise of Smaller Market Opportunities
While large enterprises dominate the healthcare AI market, smaller start-ups are finding success by focusing on niche segments, including solutions tailored to small- and medium-sized practices. This trend opens new avenues for traditional players to diversify their offerings and serve underrepresented markets.

Organisations can capitalise on this by developing or acquiring technologies that cater to these specialised needs, strengthening their position in the broader ecosystem. Addressing niche markets not only diversifies revenue streams but also fosters deeper relationships with a wider range of healthcare providers, ensuring more equitable access to innovation.
 
A Roadmap for Enterprises
 
To capitalise on the transformative potential of digital health, organisations must embrace a structured yet adaptable approach - one that balances ambitious innovation with operational pragmatism. Crucially, this requires a willingness to engage with unconventional thinkers and disruptive technologies, even when they challenge traditional corporate cultures. The following roadmap outlines five essential steps to navigate this landscape effectively:

1. Define Strategic Objectives Enterprises must first identify high-impact priorities that leverage their core strengths while addressing pressing market needs. Whether it is optimising clinical workflows, deploying AI-driven predictive analytics, or expanding virtual care capabilities, these objectives should be grounded in data insights, market intelligence, and an awareness of industry shifts. The key is to ensure that investments drive meaningful, measurable outcomes rather than just becoming exercises in experimentation.

2. Foster Strategic Partnerships The pace of change demands collaboration across diverse stakeholders, from start-ups to research institutions and tech giants. Partnering with disruptive innovators - even those whose mindsets differ from conventional corporate paradigms - can accelerate development cycles, introduce fresh perspectives, and unlock novel approaches to patient engagement or operational efficiency. Beyond innovation, these alliances also help enterprises navigate regulatory challenges and enhance system interoperability, ensuring that emerging solutions integrate seamlessly into existing care frameworks.

3. Invest in Talent and Skills Development Transformation is as much about people as it is about technology. Enterprises must cultivate a workforce equipped with expertise in AI, cloud computing, data science, and healthcare informatics. This requires a multi-pronged approach: reskilling existing employees, recruiting domain specialists, and fostering a culture that values continuous learning and cross-disciplinary collaboration. Encouraging interaction between clinical and technical teams ensures that solutions remain grounded in the realities of care delivery, enhancing both adoption and long-term efficacy.

4. Leverage M&A for Strategic Advantage Acquiring innovative companies can provide a fast-track route to leadership in emerging domains such as cybersecurity, data integration, and patient-centric engagement platforms. A disciplined approach to M&A allows enterprises to complement organic innovation efforts, filling critical capability gaps while maintaining alignment with overarching business and care objectives. However, success in this arena depends not just on financial transactions but also on integrating acquired innovations in ways that preserve their disruptive potential rather than diluting it within rigid corporate structures.

5. Adopt Agile Operating Models Agility is essential in an environment where regulatory frameworks, technological advancements, and consumer expectations evolve rapidly. Enterprises must embrace iterative development, cross-functional collaboration, and rapid prototyping to ensure solutions remain adaptive, user-focused, and future-proof. Crucially, an agile mindset must extend beyond product development to enterprise-wide decision-making - enabling organisations to pivot swiftly in response to emerging trends and disruptive forces.

By adopting this roadmap, enterprises can unlock new frontiers in digital health, fostering innovation, enhancing care delivery, and driving sustainable growth. Success will depend not only on technological sophistication but also on a openness to new ways of thinking - particularly those introduced by disrupters who may not conform to legacy corporate norms but hold the key to the next breakthrough.
 
Takeaways

The time for cautious, incremental change in healthcare has passed. The digital health revolution is not a hypothetical future - it is happening now, and the stakes could not be higher. Organisations that fail to engage with disrupters will find themselves outpaced, outmanoeuvred, and ultimately obsolete in a market that rewards speed, innovation, and adaptability.

Healthcare leaders must reject the outdated notion that disruption is a threat to stability. Stability is an illusion in an industry undergoing significant changes. The true risk lies in standing still while the landscape transforms around you. The $10bn in venture funding that flooded digital health in 2024 is not just a financial trend - it is a signal that the future of healthcare belongs to those willing to think beyond the limits of legacy systems and embrace a new paradigm driven by AI, virtual care, and precision medicine.

The choice is clear: disrupt or be disrupted.
view in full page